Search
Favezelimab
go.drugbank.com/drugs/DB16729InvestigationalFavezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A
PAT-1251
go.drugbank.com/drugs/DB16735InvestigationalPAT-1251 is under investigation in clinical trial NCT04054245 (PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocytosis Myelofibrosis
MK-886
go.drugbank.com/drugs/DB16739ExperimentalMK-886 is an experimental inhibitor of leukotriene synthesis.
Categories: Heterocyclic Compounds, 2-RingRP-67580
go.drugbank.com/drugs/DB16742ExperimentalCategories: Heterocyclic Compounds, 2-Ring, Neurokinin-1 Receptor AntagonistsCytochalasin B
go.drugbank.com/drugs/DB16766ExperimentalCategories: Heterocyclic Compounds, 2-RingSynonyms: Cytochalasin B, Cytochalasin-BLutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigationalIt consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. … Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent.
Categories: Compounds used in a research, industrial, or household settingProducts: 1 PluvictoAdlinacogene civaparvovec
go.drugbank.com/drugs/DB16788Investigational[L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706] … Adlinacogene civaparvovec is an investigational _in vivo_ genome editing therapeutic product.
Lixmabegagene relduparvovec
go.drugbank.com/drugs/DB16816InvestigationalLixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). … It is under development for the treatment of GM1 gangliosidosis.[L45929]